A carregar...
Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
Ibrutinib has emerged as a promising therapy for patients with chronic lymphocytic leukemia (CLL) who are nonresponsive to standard therapies. The refractory state of monocytes and T-cell exhaustion in patients with CLL could explain the morbidity and mortality reported in these patients. We studied...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5213769/ https://ncbi.nlm.nih.gov/pubmed/28123879 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1242544 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|